HUMAN TRIALS of the first ‘fridge-free’ vaccines that could reduce waste and barriers to global vaccine deployment have been successful. The randomised trial involved healthy adult participants who received either the SPVX02 vaccine or established comparator vaccines. The only notable side effects were comparable to those observed with currently available tetanus-diphtheria booster vaccines. If successful, the technology could represent a major shift in vaccine distribution and immunisation efforts globally. Safety, tolerability, and immunogenicity of SPVX02, a room temperature-stabilised tetanus-diphtheria vaccine, compared to two established tetanus-diphtheria booster vaccines: a multicentre, single-blind, randomised, first-in-human phase 1 trial in the UK.